MEDITRIAL OPENS OFFICES IN NEW YORK CITY
Meditrial, best-in-class CRO for medical devices, launches new office in the heart of Manhattan. The New York city office is a brand new space to bring together people who share a dedication to innovation. Come visit the Training Center or enjoy the working lounge: we will welcome all members of our research community.
Our office remains open during the COVID-19 emergency. Meditrial’s New York City Squad is readily available to help, support and assist US customers from our new location in New York City.
Meditrial USA Inc.
866 United Nations Plaza #484
10017 NY, NY
Phone +1 646 933 1025
Need more information? Call Meditrial at the number below or send us an email
Table of Contents
Build a Defensible Clinical Evidence Strategy Under EU MDR
Build a defensible clinical evidence strategy under MDR Annex XIV, from the clinical evaluation plan to PMCF and notified body review.
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
